Search Bar & Filters
Found 79 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the effectiveness and safety of HBS-301 in adults aged 18 years and older with narcolepsy. The study focuses on treating excessive daytime sleepiness EDS, cataplexy, sleepinesswakefulness, and fatigue in this population. Participants will be randomly assigned to receive either HBS-301 tablets or matching placebo tablets once daily in the morning upon waking during an 8-week double-blind treatment period. After this, participants may opt into a one-year open-label extension where all receive HBS-301. The study begins with a screening and baseline period lasting up to 28 days, followed by the treatment phases, and concludes with a 30-day safety follow-up. During the study, participants will undergo various assessments including the Epworth Sleepiness Scale to measure changes in daytime sleepiness, evaluations of cataplexy frequency, fatigue levels, sleepinesswakefulness tests, and quality of life questionnaires. Safety will be monitored throughout the entire study duration of approximately 16 months. Participants will have scheduled visits for assessments during each phase to track treatment effects and safety.
Actively Recruiting
Researchers are studying the use of a personalized mobile application called SHIFT to improve sleep in night shift workers with Shift Work Sleep Disorder. The study aims to build evidence for fair access and effective use of this precision sleep medicine tool, which uses body-clock data collected from an Apple Watch to provide tailored light exposure schedules. The trial is randomized and double-blind, comparing the SHIFT app to a waitlist control group over a period of up to eight months. Participants in the SHIFT app group receive access codes to download the app and attend an orientation session. They then follow a four-week period of guided app use where they start their day with the app and plan their activities based on its recommendations, using the app about four times per week. This is followed by self-directed use, with a booster session at four months that includes two additional weeks of guided use before continuing self-directed use until the study ends. The waitlist control group completes questionnaires during the first eight months and may choose to use the app afterward if still working night shifts. During the study, participants complete surveys and app usage is monitored to assess engagement, experience, and accuracy of the app on different platforms. The main outcomes include evaluating the effect of SHIFT on participant-centered results and comparing app versions from enrollment through eight months. Additional assessments explore factors that help or hinder app use. The study involves regular evaluations over the first eight months, with follow-up and safety monitoring continuing until the study concludes in mid-2027.
Actively Recruiting
Researchers are evaluating the drug efruxifermin EFX in adults with compensated cirrhosis caused by NASH Nonalcoholic Steatohepatitis or MASH Metabolic Dysfunction-Associated Steatohepatitis. This phase 3, randomized, double-blind, placebo-controlled study aims to assess the safety and efficacy of EFX in slowing disease progression and improving liver health over several years. Participants will be randomly assigned to receive either EFX 50 mg or a placebo, both given by subcutaneous injection. The study includes two cohorts one with biopsy-proven compensated cirrhosis and metabolic features, and another diagnosed either by biopsy or non-invasive methods. Treatment and follow-up will continue for up to five years to monitor outcomes. Throughout the study, participants will undergo regular assessments including liver fibrosis markers, liver injury markers, lipoproteins, insulin sensitivity, glycemic control, and body weight changes. Safety will be closely monitored through laboratory tests, ECGs, ultrasounds, and vital signs. The primary outcome measures include time to significant clinical events like disease progression or liver decompensation and improvements in fibrosis and steatohepatitis, with follow-up extending up to five years.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.
Actively Recruiting
Researchers are evaluating the safety and tolerability of TAK-861 in people with narcolepsy type 1 NT1. This study focuses on participants who have already been exposed to TAK-861 doses in previous clinical trials. The goal is to monitor how TAK-861 affects symptoms such as excessive daytime sleepiness and cataplexy episodes over a long period. All participants in this trial will receive TAK-861 tablets. Those who previously received a placebo will be randomly assigned to one of the TAK-861 dose groups. The study is a long-term extension conducted worldwide and is expected to last approximately five years or until the product is approved or the study is stopped. Participants may switch doses as needed and will attend multiple clinic visits, some of which can be done at home. Throughout the trial, participants will be regularly assessed for safety by tracking any treatment-emergent adverse events. Researchers will also measure changes in sleep latency, sleepiness scores, and cataplexy rates compared to baseline data from earlier trials. Follow-up assessments will take place four weeks after the final dose to monitor ongoing effects and ensure participant safety.
Actively Recruiting
Researchers are comparing the effectiveness of two combinations of drugs, teclistamab with daratumumab and lenalidomide Tec-DR, and talquetamab with daratumumab and lenalidomide Tal-DR, against the combination of daratumumab, lenalidomide, and dexamethasone DRd in adults with newly diagnosed multiple myeloma who are not candidates for stem cell transplant. This Phase 3 trial focuses on evaluating treatment outcomes and survival rates over an extended period. Participants will be randomly assigned to one of three groups one receiving teclistamab by subcutaneous injection combined with daratumumab and oral lenalidomide another receiving talquetamab by subcutaneous injection combined with daratumumab and lenalidomide and the third receiving daratumumab by subcutaneous injection along with oral lenalidomide and dexamethasone, which may be given orally or intravenously. Treatments will be administered according to protocol, with close monitoring throughout the study. During the study, participants will undergo regular evaluations over up to nine years, including assessments of disease progression, survival, response to treatment, and quality of life using various questionnaires. Safety will be monitored through laboratory tests, physical exams, vital signs, electrocardiograms, and tracking of any adverse events. Researchers will also measure drug concentrations and immune responses to the study drugs. Participation may last until disease progression, death, or the end of the study period.
Actively Recruiting
Researchers are comparing the effects of adding immunotherapy drugs, brentuximab vedotin and nivolumab, to the standard chemotherapy treatment, with or without radiation, for patients diagnosed with early stage classical Hodgkin lymphoma stage I or II. This phase III trial aims to evaluate whether this combination improves survival and reduces side effects compared to standard treatment alone. The study includes both children and adults aged 5 to 60 years with newly diagnosed disease and measurable tumors. Participants first receive two cycles of the ABVD chemotherapy regimen. After treatment, imaging scans determine their early response, classifying them as rapid or slow responders and stratifying them by risk status favorable or unfavorable. Based on these factors, patients are assigned to one of eight different treatment arms involving variations of chemotherapy, immunotherapy, and involved-site radiation therapy. Treatments are given in cycles every 28 days, with some arms receiving additional cycles or radiation depending on response and risk. Throughout the trial, participants undergo regular imaging tests such as PET, CT, or MRI scans to monitor disease and treatment effects. Blood samples may also be collected. Following treatment completion, patients will be followed up with visits every 3 months for the first year, then every 6 months for two years, and annually up to 12 years. Researchers will assess outcomes including progression-free survival, overall survival, adverse events, patient-reported quality of life, fatigue, cognitive function, and long-term side effects.
Actively Recruiting
Researchers are evaluating ALKS 2680 tablets in adults with Narcolepsy Type 1 NT1 to measure reductions in daytime sleepiness, sudden muscle tone loss cataplexy, and overall disease symptoms. This phase 3 clinical trial compares the effects of ALKS 2680 with placebo tablets to assess their impact on these key aspects of NT1. Participants are randomly assigned to one of three groups a placebo group or one of two different dose groups of ALKS 2680 tablets. All participants take their assigned oral tablets daily for 12 weeks. The study uses a triple-blind design, meaning that participants, investigators, and others involved do not know which treatment is being given. During the 12-week treatment, participants will be monitored for changes in sleep latency using the Maintenance of Wakefulness Test, daytime sleepiness via the Epworth Sleepiness Scale, weekly cataplexy rates, and other cognitive and fatigue assessments. Safety is tracked through the incidence of treatment-emergent adverse events up to 14 weeks. Outcome measures also include patient global impressions and narcolepsy severity scales to evaluate overall disease impact.
Actively Recruiting
Researchers are evaluating the effects of ALKS 2680 tablets on reducing daytime sleepiness and symptoms in adults diagnosed with Narcolepsy Type 2 NT2. This Phase 3, randomized, double-blind, placebo-controlled study aims to assess the efficacy and safety of three different doses of ALKS 2680 compared with placebo tablets. The study is sponsored by Alkermes, Inc. and uses a parallel design to compare outcomes. Participants are randomly assigned to receive one of three dose levels of ALKS 2680 tablets or a placebo, taken orally once daily for 12 weeks. The study includes a triple-blind approach to ensure unbiased results. The primary focus is on measuring changes in mean sleep latency using the Maintenance of Wakefulness Test MWT from baseline through Week 12. Secondary outcome measures include assessments of sleepiness, cognitive complaints, fatigue, and global impression scales. Throughout the 12-week treatment, participants will undergo various evaluations such as the Epworth Sleepiness Scale, Patient Global Impression-Severity scale, and Psychomotor Vigilance Task, among others. Safety is monitored by recording treatment emergent adverse events up to 14 weeks. This study includes adults aged 18 to 70 years with a confirmed diagnosis of NT2. Overall participation spans just over 12 weeks, with regular assessments to track symptom changes and treatment effects.
Actively Recruiting
Researchers are evaluating the optimal doses of the drug E2086 compared to placebo in adults with narcolepsy, a condition characterized by excessive daytime sleepiness EDS. The study focuses on reducing EDS as measured by the Mean Sleep Latency MSL using the first four maintenance of wakefulness tests MWTs. This Phase 2 trial includes participants diagnosed with either narcolepsy type 1 NT1 or type 2 NT2 within the last 10 years. Participants will be randomly assigned to receive either E2086 or a matching placebo tablet taken orally once daily for four weeks at low, middle, and high doses. Each dosing period is separated by a washout period of at least seven days, with a total treatment duration of approximately 14 weeks. This design allows comparison of the effects of different doses of E2086 on narcolepsy symptoms. During the study, participants will undergo assessments to measure changes in sleep latency, cataplexy episodes, and sleepiness scales. Additional safety evaluations include monitoring for adverse events, laboratory tests, vital signs, ECG parameters, and suicidality assessments. Blood samples will be collected to analyze drug concentration levels. The study involves regular monitoring up to Day 113 and aims to assess both efficacy and safety over the course of treatment and follow-up.
1-10 of 79
1